Nigel Clark Email & Phone Number

Oxford, Gb

Dr Clark serves as Chief Business Officer of Nucleome Therapeutics. With over 20 years of commercial and senior managerial experience in the biotech and pharma industry he most recently served as SVP Business Development and a member of the executive team at Kymab which was successfully divested in2021 to Sanofi for $1.1bn upfront and a further $300M of success-based milestones. His specialities are in business and corporate development, licensing and M&A and he has negotiated and executed over 20 major transactions.Previous roles include Chief Business Officer at Syntaxin, (divested to Ipsen Pharma), VP of Business Development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. Dr Clark has also held leadership roles at Ribotargets and British Biotech and was co-head of the biotech business unit at Datamonitor. He was awarded a Ph.D. from the university of Reading for research conducted into HIV gene regulation and completed his scientific training as a post-doctoral scientist at the department of biochemistry, University of Oxford.

Over 20 years of commercial and managerial experience in the biotech and pharma industry. Dr Clark was formerly Chief Business Officer at Syntaxin, (divested to Ipsen Pharma), Vice-President of business development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. Dr Clark has also held leadership roles at Ribotargets and British Biotech and was co-head of the biotech business unit at Datamonitor

Cambridge, Cambs, Gb